By Jill Feldman, EGFR Resisters Co-Founder Posted: December 11, 2019 Jill Feldman I was so glad to see the article by Dr. Amy Moore on PDX models in the October […] Read more
PROVIDER RESOURCES
MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC
INDUSTRY SUPPORTED
COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events